Delivery Order SPE2DB24D2100-SPE2DB25FBGLT
- Not listed
- The Defense Logistics Agency (DLA) Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on July 18, 2025, for Tezspire 210 mg/1.91 mL pen auto-injectors valued at $4,687.18, with completion scheduled for August 8, 2025. This is a firm fixed-price delivery order with no set-aside designation, meaning it was awarded through open competition. The contract is to be performed at the company's corporate office location in Conshohocken, Pennsylvania. This delivery order is a...
- The Defense Logistics Agency awarded a delivery order valued at $4,687.18 to AmerisourceBergen Drug Corp for Tezspire 210 mg/1.91 ml pen auto-injectors on June 9, 2025, with a completion date of July 1, 2025. This firm fixed-price, non-set-aside delivery order represents a competitive award under the company's existing Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999.99 billion global pharmaceutical support vehicle running through December 2026. The product will be...
- The Defense Logistics Agency awarded a $4,939.58 delivery order to AmerisourceBergen Drug Corp for Tezspire 210 mg/1.91 ml pen auto-injectors, with an ultimate completion date of November 12, 2025. This non-set-aside contract represents a firm fixed price delivery order issued on October 21, 2025, and will be performed at the awardee's Corporate Office location in Conshohocken, Pennsylvania. Tezspire is a biologic monoclonal antibody treatment used in severe asthma management, reflecting the...
- The U.S. Defense Logistics Agency Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on July 31, 2025, for the supply of Tezspire 210 mg/1.91 ml pen auto-injectors. This firm fixed-price delivery order, valued at $4,687.18, carries an ultimate completion date of August 21, 2025, and represents a non-competitive award with no set-aside designation. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, will fulfill this order from its corporate office...
- The Defense Logistics Agency (DLA) awarded a $9,374.36 delivery order to AmerisourceBergen Drug Corp for Tezspire 210 mg/1.91 ml pen injectors on April 22, 2025, with completion scheduled for May 13, 2025. This is a firm fixed price, non-set-aside contract with performance at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued...
- The Defense Logistics Agency awarded a $4.7K delivery order to AmerisourceBergen Drug Corp on September 8, 2025, for the supply of Tezspire 210 mg/1.91 mL pen injections. This competitively awarded, firm fixed-price contract carries an ultimate completion date of September 29, 2025, and will be fulfilled at AmerisourceBergen's corporate headquarters in Conshohocken, Pennsylvania. The delivery order is issued under AmerisourceBergen's broader Indefinite Delivery Contract (IDC) with DLA Troop...
- The Defense Logistics Agency awarded a delivery order valued at $7,030.77 to AmerisourceBergen Drug Corp on August 15, 2025, for the supply of Tezspire 210 mg/1.91 mL pen auto-injectors. The contract is non-competitive, firm fixed price delivery order with an ultimate completion date of September 8, 2025. Performance will occur at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under a larger Indefinite Delivery Contract vehicle with the...
- The Defense Logistics Agency awarded a $4,687.18 delivery order to AmerisourceBergen Drug Corp on August 12, 2025, for the supply of Tezspire 210 mg/1.91 mL pen auto-injectors. This competitively awarded, firm fixed-price contract with an ultimate completion date of September 3, 2025, represents a child order under AmerisourceBergen's larger pharmaceutical supply agreement. The product will be delivered to the company's corporate office location in Conshohocken, Pennsylvania. This delivery order...
- The Defense Logistics Agency awarded a delivery order valued at $2,343.59 to AmerisourceBergen Drug Corp for Tezspire 210 mg/1.91 mL pen auto-injectors on September 25, 2025, with an ultimate completion date of October 17, 2025. This firm fixed-price, non-set-aside contract was awarded competitively and is being performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The award represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery...
- The Defense Logistics Agency awarded a $4.7K firm fixed-price delivery order to AmerisourceBergen Drug Corp for Tezspire 210 mg/1.91 mL pen auto-injectors, with a completion date of September 17, 2025. This competitive award carries no set-aside designation and represents a single delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999.9M through December 2026. The place of performance is located in Conshohocken,...
- SPE2DB24D2100Indefinite Delivery Contract
- SPE2DB24D2100-SPE2DB25FBGLTDelivery Order
The Defense Logistics Agency (DLA) awarded a $4.69K delivery order to AmerisourceBergen Drug Corp on September 18, 2025, for the supply of Tezspire 210 mg/1.91 mL pen auto-injectors, with completion targeted for October 9, 2025. This competitively awarded, firm fixed-price delivery order carries no set-aside designation and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. Tezspire is a biologic respiratory treatment used for moderate-to-severe asthma management, reflecting the breadth of specialized pharmaceutical products that AmerisourceBergen supplies to federal healthcare systems. This delivery order is issued under AmerisourceBergen's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX and valued at $999.99M through December 2026. As a major pharmaceutical distributor and critical vendor for military and veteran healthcare systems, AmerisourceBergen maintains an extensive portfolio of federal medical procurement contracts spanning brand-name and generic medications, vaccines, medical devices, and specialized healthcare commodities. The company's capacity to fulfill this order demonstrates its established role as a primary pharmaceutical supplier supporting the Defense Health Agency and other federal healthcare programs globally.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $4.7k | 9/18/25 |